The Drugs Controller General of India (DCGI) has given approval to the CSIR and Laxai Life Sciences Private Limited to conduct clinical trial of Colchicine on COVID-19 patients, according to a statement on Saturday. Ram Vishwakarma, the advisor to the CSIR Director General, said Colchicine in combination with standard care will be an important therapeutic intervention for COVID-19 patients with cardiac co-morbidities and also for reducing pro-inflammatory cytokines, leading to faster recovery. A number of global studies have confirmed that cardiac complications during course of COVID-19 infections and post-Covid syndrome are leading to loss of many lives, and it is essential to look for new or repurposed drugs, he said. "Council of Scientific & Industrial Research (CSIR), and Laxai Life Sciences Pvt Ltd Hyderabad, have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of
from Latest News https://ift.tt/3zl6vTP
https://ift.tt/eA8V8J https://ift.tt/2LUVdkd
Home
Business
Business News
Business Standard
Latest News
Regulatory nod given to conduct clinical trials of Colchicine: CSIR
Saturday, June 12, 2021
Related Posts:
Solar project companies queue up to cash in on pre-duty benefitsFor a project bid in March, import of panels would take place between … Read More
FinMin mulls bringing DPE under itself ahead of privatisation driveMove aimed at better control over PSUs ahead of govt's ambitious priva… Read More
ASCI aims to break gender stereotypes in advertising, change mindsetsThe Advertising Standards Council of India (ASCI) is hoping to find an… Read More
DFI goes back to the future: Will changes boost infra funding in India?The Bill suggests that the government has learned from past mistake f… Read More
0 comments: